Dr Prasad Adusumilli gives a press conference at AACR 2019 on results from a phase I clinical trial showing that CAR T cell therapy, targeting the protein mesothelin, produced anti-tumour activity with no evidence of major toxicity when treating patients with advanced solid tumours.